| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||
| Chlorophyllin is a semi-synthetic derivative of chlorophyll, the green pigment found in plants that is essential for photosynthesis. -Antioxidant Activity -Detoxification -Inhibition of Tumor Growth(unknown pathway?) -Modulation of Gene Expression -Anti-inflammatory Effects Dose: 100-300mg/d split 1-3x/d Chlorophyllin — Chlorophyllin is a semi-synthetic, water-soluble copper-containing derivative mixture of plant chlorophyll, most commonly used as sodium copper chlorophyllin. It is best classified as a semi-synthetic small-molecule phytochemical derivative that also functions as a food color additive, OTC deodorant drug ingredient, and chemopreventive “interceptor” candidate rather than a validated systemic anticancer drug. Standard abbreviations include CHL and, for the common oral form, SCC (sodium copper chlorophyllin). It originates from natural chlorophyll after saponification and copper substitution to improve water solubility and stability. The strongest translational evidence is for oral reduction of carcinogen bioavailability and DNA-adduct burden in exposure settings; direct tumoricidal signaling effects are mostly preclinical, and photodynamic use is a distinct external-trigger application. Chlorophyll (Chl), the parent compound of CHL, is readily available by consumption of green vegetables.Primary mechanisms (ranked):
Bioavailability / PK relevance: Oral chlorophyllin is relatively digestive-stable and can interact with intestinal cells, but available PK data suggest limited systemic serum exposure, with significant luminal retention and efflux likely contributing to its dominant gastrointestinal interception profile. Some animal work suggests tissue distribution can occur, but standard oral use does not support assuming high free systemic tumor exposure. In-vitro vs systemic exposure relevance: Common direct anticancer in-vitro studies likely use concentrations above what is reliably achievable in systemic circulation with ordinary oral dosing. Its most credible non-PDT human effect is not high plasma tumor exposure but reduced carcinogen uptake and biomarker damage. In PDT contexts, efficacy is not ordinary concentration-driven alone and requires an external light trigger. Clinical evidence status: Human evidence is strongest for chemopreventive biomarker modulation, including a randomized placebo-controlled trial showing reduced aflatoxin biomarker burden in a high-risk population. Evidence for direct cancer treatment remains preclinical or adjunctive/emerging, while newer studies in radiation-related injury are not yet proof of anticancer efficacy. Mechanistic table
TSF legend: P: 0–30 min |
| Source: |
| Type: |
| Tumor cell invasion is a critical process in cancer progression and metastasis, where cancer cells spread from the primary tumor to surrounding tissues and distant organs. This process involves several key steps and mechanisms: 1.Epithelial-Mesenchymal Transition (EMT): Many tumors originate from epithelial cells, which are typically organized in layers. During EMT, these cells lose their epithelial characteristics (such as cell-cell adhesion) and gain mesenchymal traits (such as increased motility). This transition is crucial for invasion. 2.Degradation of Extracellular Matrix (ECM): Tumor cells secrete enzymes, such as matrix metalloproteinases (MMPs), that degrade the ECM, allowing cancer cells to invade surrounding tissues. This degradation facilitates the movement of cancer cells through the tissue. 3.Cell Migration: Once the ECM is degraded, cancer cells can migrate. They often use various mechanisms, including amoeboid movement and mesenchymal migration, to move through the tissue. This migration is influenced by various signaling pathways and the tumor microenvironment. 4.Angiogenesis: As tumors grow, they require a blood supply to provide nutrients and oxygen. Tumor cells can stimulate the formation of new blood vessels (angiogenesis) through the release of growth factors like vascular endothelial growth factor (VEGF). This not only supports tumor growth but also provides a route for cancer cells to enter the bloodstream. 5.Invasion into Blood Vessels (Intravasation): Cancer cells can invade nearby blood vessels, allowing them to enter the circulatory system. This step is crucial for metastasis, as it enables cancer cells to travel to distant sites in the body. 6.Survival in Circulation: Once in the bloodstream, cancer cells must survive the immune response and the shear stress of blood flow. They can form clusters with platelets or other cells to evade detection. 7.Extravasation and Colonization: After traveling through the bloodstream, cancer cells can exit the circulation (extravasation) and invade new tissues. They may then establish secondary tumors (metastases) in distant organs. 8.Tumor Microenvironment: The surrounding microenvironment plays a significant role in tumor invasion. Factors such as immune cells, fibroblasts, and signaling molecules can either promote or inhibit invasion and metastasis. |
| 6073- | CHL, | GEM, | Chlorophyllin exerts synergistic anti-tumor effect with gemcitabine in pancreatic cancer by inducing cuproptosis |
| - | in-vitro, | PC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:218 Target#:324 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid